Skip Navigation
Men's Newsletter
October 1, 2012
In this Issue
• Genes May Influence Impotence After Prostate Radiation
• Newly Approved Imaging Agent Helps Find Prostate Cancer

Genes May Influence Impotence After Prostate Radiation

Preliminary research suggests genetic analysis might help men assess their risk

THURSDAY, Sept. 27 (HealthDay News) -- Men with certain gene mutations may be at higher risk for erectile dysfunction after receiving radiation therapy for prostate cancer than other patients, a new study suggests.

Although far from clinical use now, genetic analysis may someday play a role in personalizing treatment for prostate cancer patients, researchers said.

"We believe there are genetic factors that make patients more likely to develop complications from treatment," said lead researcher Barry Rosenstein, from the department of radiation oncology at Mount Sinai School of Medicine in New York City.

Erectile dysfunction, or impotence, is a common side effect of radiation therapy, he said. Urinary problems and rectal bleeding also can arise from radiation therapy, he added.

"In this paper, we found 12 markers we feel are strongly associated with developing erectile dysfunction, but also we found a similar number of other markers associated with urinary problems and rectal bleeding," Rosenstein said.

The goal of the research is to develop a test that will help patients and doctors choose the best treatment options, he explained.

Combining genetic factors with other considerations such as cancer stage and results from other treatments, doctors and patients will have a better way of individualizing a treatment plan, Rosenstein suggested.

"The results are looking good, but they are not ready to be included in a clinical trial," Rosenstein said. That won't happen for three to five years, he added.

Rosenstein believes these genetic markers add to other known risk factors for these side effects for a more complete assessment of risks.

The report was published online Sept. 27 in the International Journal of Radiation Oncology, Biology, Physics.

For the study, Rosenstein's team looked at almost 600 men treated with implanted and/or external beam radiation and hormone therapy for prostate cancer. Of this group, 260 experienced erectile dysfunction after treatment.

The researchers looked for differences in the genes of the men who became impotent and those who didn't.

The investigators found 12 gene mutations called single nucleotide polymorphisms (SNPs) associated with a greater risk of developing erectile dysfunction after radiation therapy for prostate cancer.

However, while the researchers uncovered an apparent connection between the mutations and erectile dysfunction, they did not prove a cause-and-effect relationship.

Dr. Anthony D'Amico, chief of genitourinary (uro-genital) radiation oncology at Brigham and Women's Hospital in Boston, said the research is valuable. "These type of studies are very important and will, I think, be the future of how we decide what treatments are best in which individuals," he said.

"It will as well identify who has more sensitivity to one treatment or another with regard to side effects," he added.

D'Amico cautioned that this is preliminary data so it needs to be verified in other men, he said.

"In addition, we have to make sure, even if it is validated, it provides information that we don't already have," he noted.

To be useful, a genetic analysis needs to identify men who don't already have other known risk factors for erectile dysfunction, D'Amico explained. Those other risk factors include obesity and diabetes.

Beyond that caveat, genetic analysis is the future of individualized treatment for prostate cancer, he said.

The U.S. National Cancer Institute estimates that in 2012 nearly 242,000 men will be diagnosed with prostate cancer and more than 28,000 will die from the disease.

More information

For more information on prostate cancer, visit the U.S. National Cancer Institute.

Newly Approved Imaging Agent Helps Find Prostate Cancer

But not replacement for actual tissue testing, FDA says

WEDNESDAY, Sept. 12 (HealthDay News) -- Choline C 11, an imaging agent used for positron emission tomography (PET) testing, has been approved to help detect recurring prostate cancer, the U.S. Food and Drug Administration said Wednesday in a news release.

The injected substance helps produce an image that allows doctors to identify tissues to test for the disease, the agency said. It warned that PET testing was not a substitute for testing of the actual tissue.

PET testing is performed in men who have elevated blood levels of prostate specific antigen (PSA), a sign that prostate cancer could be present, the FDA said.

In reviewing four previously published studies, the agency said it found that "at least half" of men who had abnormalities detected in PET scans "also had recurrent prostate cancer confirmed by tissue sampling of the abnormal areas."

The FDA said side effects of the newly approved agent were limited to "an uncommon, mild skin reaction at the injection site."

The agent is manufactured and distributed by the Mayo Clinic PET Radiochemistry Facility, in Rochester, Minn.

More information

To learn more about prostate cancer, visit the U.S. National Cancer Institute.

Copyright © 2012 ScoutNews, LLC. All rights reserved.